Why did Novo Nordisk stock fall today?

Novo Nordisk stock dropped up to 17% after CagriSema missed its primary endpoint and underperformed Eli Lilly tirzepatide in a head‑to‑head readout. That result weakened confidence in the next‑generation obesity roadmap. Investors quickly repriced growth and margin assumptions, pressuring Danish equities and the krone as risk appetite faded.

What is CagriSema and how did it compare?

CagriSema is Novo’s obesity combo candidate. In the latest study, it failed the primary endpoint and lagged Eli Lilly tirzepatide on key measures. The market had hoped for a clear efficacy advantage. Without that, future peak sales and pricing power look less certain, which weighed on Novo Nordisk stock.

How should Swiss investors think about currency risk now?

Many Swiss holders own USD or DKK lines. CHF strength can dampen returns, while hedged share classes reduce FX swings but add costs. Choose a hedge based on your time horizon and cash needs. Do not let one volatile session in Novo Nordisk stock drive a short‑term, reactive currency switch.

What are the next catalysts for Novo Nordisk stock?

Key drivers include management’s plan for more CagriSema studies, any comparative data updates, payer and reimbursement signals in Europe, and the next earnings report on 6 May 2026. Stabilizing supply and demand in the obesity franchise could also lift sentiment if execution remains solid.

Global Market Insights

NVO Stock Today, February 24: CagriSema Miss Sparks 17% Plunge

ByDanny Kontos February 24, 2026February 24, 2026

Novo Nordisk stock slid as much as 17% today after fresh CagriSema trial results missed the primary endpoint and trailed Eli Lilly’s tirzepatide in a head‑to‑head study. The selloff hit Danish equities and the krone, and it matters for Swiss portfolios with healthcare exposure. We break down what changed in the obesity narrative, why the move may not end in one day, and what investors in CH should watch before making any decision on Novo Nordisk stock.